INTRODUCTION
Diabetes mellitus is a prevalent disease on the rise with serious impact on healthcare costs and patient safety. In the United States alone there are 29.1 million patients with diabetes, including 8.1 million undiagnosed cases [1] .
The majority are patients diagnosed with type 2 diabetes, and approximately 1.25 million patients are diagnosed with type 1 diabetes [1] . Long-term complications of diabetes include microvascular complications, stroke, kidney disease, blindness, and neuropathy and it is well established that tight glycemic control and timely treatment improve outcomes and reduce complications [2, 3] . Patients with type 1 diabetes require continuous insulin infusion or multiple daily injections (MDI) of insulin. Due to the decline of islet cell function over time it is likely that many patients with type 2 diabetes will eventually require insulin therapy as treatment is progressed.
In type 2 diabetes, insulin therapy is typically initiated with a single injection of basal insulin, and if targets are not met after active titration patients may be progressed to a basal-bolus regimen with MDI. Basal insulin therapy is sufficient for many patients; however, despite optimization of basal insulin evidence suggests \40% of patients with type 2 diabetes achieve glycemic targets [3] . In the Treating to Target in Type 2 diabetes study (ClinicalTrials.gov identifier, NCT00184600), most patients (82%) required insulin intensification to include mealtime bolus insulin by 3 years to achieve glycemic targets [4] .
Increased complexity of treatment regimens leads to decreased adherence, which in turn impacts efficacy [5] [6] [7] . Insulin non-adherence has been correlated with patient perceptions of regimen inflexibility and the burden on one's lifestyle [8] . Surprisingly, 72% of patients on MDI therapy report they never take injections outside of the home [9] . Addressing these treatment barriers may improve patient outcomes.
V-Go Ò (Valeritas, Inc., Bridgewater, NJ, USA), shown in Fig. 1 , is a disposable, wearable insulin delivery device that delivers a continuous basal rate of insulin, as well as on-demand mealtime dosing. V-Go is available in basal rates of 20, 30, or 40 units/24 h and can administer up to an additional 36 units of insulin for mealtime bolus dosing in 2 unit increments. V-Go is filled with U-100 fast-acting insulin (insulin lispro, rDNA origin or insulin aspart, rDNA origin have been tested by Valeritas and found safe for use in V-Go) [10] and is affixed to the skin. The push of a button inserts a 4.6 mm 30 gauge stainless steel needle subcutaneously, which initiates delivery of a continuous preset basal rate of insulin. Patients can self-administer mealtime bolus doses by pressing the bolus ready button and the bolus delivery button through clothing for discreet insulin administration. V-Go uses a hypoallergenic and latex-free adhesive to adhere to the skin, and is designed to be removed and replaced every 24 h. Use of V-Go has been associated with improved glycemic control [11] [12] [13] . An investigation done by Rosenfeld and colleagues showed a decrease in glycated hemoglobin (HbA1c) when patients were switched to insulin delivery by V-Go, and an increase in HBA1c following the cessation of V-Go [11] . The current study examined real-world use of V-Go in a specialized diabetes system. The purpose of this study was to evaluate glycemic control after patients with sub-optimally controlled diabetes on previous therapeutic regimens were switched to insulin therapy delivered by V-Go.
METHODS

Study Design and Criteria
The study was conducted as a retrospective review of the electronic medical record (EMR) previously prescribed basal or basal-bolus insulin therapy or naïve to insulin therapy, with or without anti-hyperglycemic medications; and switched to insulin delivery by V-Go; and (5) a minimum of one subsequent HbA1c lab value on V-Go. Patients were excluded for (1) history of treatment with U-500 insulin preceding V-Go initiation or the non-Food and Drug Administration approved utilization of U-500 insulin delivery by V-Go;
(2) receiving insulin delivery via an insulin pump immediately preceding V-Go initiation; For all of the tests, a spatial power covariance structure was modeled to adjust for the differences in the number of days between time periods. Changes from baseline for all analyses are expressed as least-squares means (LSM) with 2-sided 95% confidence intervals (CIs) unless otherwise noted.
If any ANOVA or ANCOVA resulted in a significant P value (P\0.05) the analysis was followed by pairwise comparisons using Tukey's adjustment for multiplicity. All tests were performed using proc mixed in SAS v.9.3 (SAS Institute Inc., Cary, NC, USA). 26.86 ± 8.96 weeks. Results will therefore be presented for 14-and 27-week visits.
RESULTS
Study Population
One-hundred and seventy-five patients were diagnosed with type 2 diabetes and 29 patients with type 1 diabetes or LADA. The majority of patients (n = 180) were using insulin at baseline and 24 patients were naïve to insulin at baseline. Patient characteristics are shown in Tables 1 and 2 . The TDD of insulin was greater in patients with type 2 diabetes than in patients with type 1 diabetes or LADA. Patient-reported baseline TDD was 10% lower than the lower limit and 22% lower than the upper limit of the prescribed insulin dose range. At baseline, the majority of patients (66%) were taking concomitant anti-hyperglycemic medications with 53% of patients included in the study having already escalated treatment to two or more agents. As is to be expected in a comprehensive system where patients are referred for treatment, comorbidities were common with a majority of patients also diagnosed with hypertension (83%) and hyperlipidemia (69%).
Glycemic Response to V-Go
Overall, there was a significant decrease in HbA1c after switching to V-Go across all patient types. The HbA1c LSM change for the overall patient population and by types of diabetes is displayed in Fig. 2 . HbA1c results were also analyzed by use of insulin at baseline prior to switching to V-Go. In patients administering insulin at baseline, the reduction in mean HbA1c from baseline to 14 weeks was -1.34% (-1.51% to -1.18%; P\0.001) and from baseline to 27 weeks was
Patients naïve to insulin prior to baseline experienced the most substantial decrease in mean HbA1c after switching to V-Go, with a reduction in mean HbA1c from baseline to 14 weeks of -2.97% (-3.56% to -2.38%; P\0.001) and a reduction from baseline to 27 weeks of -3.44% (-4.12% to -2.75%;
P\0.001). . 3 ). Significant and progressive reductions in HbA1c were seen in all three subsets at both the 14-week and 27-week timepoints (P\0.001).
The distribution of HbA1c values for the study population at baseline was compared to the distribution at both follow-up HbA1c time points. Figure 4 
Insulin Dose on V-Go
Prescribed daily basal insulin and TDD at V-Go initiation, 14, and 27 weeks were analyzed after switching to V-Go for those patients administering insulin prior to V-Go ( Fig. 5 ). For both TDD and basal insulin doses, there were statistically significant reductions in insulin requirements after switching to V-Go (P\0.001). At 27 weeks, TDD on V-Go was 33% lower than the lower limit and 41% lower than the upper limit of the prescribed baseline dose range. Basal insulin rates were 39% lower than the lower limit and 46% lower than the upper limit of the prescribed baseline dose range. The In patients naïve to insulin at baseline the mean TDD of insulin was 54 units at 27 weeks.
Of this mean TDD 57% was basal insulin and 43% was mealtime bolus insulin.
Mean however, there was no significant difference in mean TDD between any of the groups after switching to V-Go. Patients with an increase in (9), cost/insurance coverage (7) , transitioned to an insulin pump (5), weight gain (2), undetermined reason (2), and did not prefer V-Go, pain, GI effect, hyperglycemia, hypoglycemia and lack of adherence to skin (1 each). Patient baseline characteristics were similar between those that continued therapy and those that discontinued V-Go.
DISCUSSION
In this study, we examined the outcomes of 204 patients after being switched to insulin therapy delivered by V-Go. Due to the progressive nature of diabetes, treatment intensification is required to maintain acceptable blood glucose control and decrease the risk of adverse outcomes. Insulin is the most consistently effective and potent way to improve blood glucose control [16, 17] . Guidelines recommend basal insulin therapy plus mealtime boluses as a treatment intensification option delivered by either MDI or continuous subcutaneous infusion [18] . This retrospective analysis identified patients from a specialized comprehensive diabetes care clinic setting who had not achieved adequate blood glucose control with their current treatment regimen and were changed to insulin delivery with V-Go according to clinician judgment. The multi-clinic system treats a large number of patients who are referred from primary care sites for specialized care, which is reflected in the mean duration of diabetes of 13.7 years and a baseline HbA1c of 9.63% in the study population. After switching to V-Go, glycemic control improved regardless of patient type, baseline TDD, HbA1c, or treatment regimen Because insulin regimens can impact daily routines and lifestyles, convenience and ease of administration are a consideration when initiating and titrating insulin regimens. Intensification from basal insulin therapy to MDI therapy may be delayed due to the inconvenience of multiple injections and patients often do not adhere to a MDI regimen especially when injections are required to be taken outside the home. Data from this study for insulin dosing prior to V-Go use support this lack of adherence; in patients using insulin prior to V-Go, the patient-reported TDD of insulin dose was 10% lower than the lower limit and 22% lower than the upper limit of the prescribed range, confirming that patients were using less insulin than prescribed. V-Go may improve adherence with administering bolus doses considering insulin is readily available Fig. 5 Insulin dosage. a Basal insulin dose/rate. b Insulin TDD. Data reflects insulin cohort (n = 180). Insulin data are LSM with corresponding 95% confidence intervals derived from a repeated measures mixed model for baseline upper and lower limit prescribed dose range compared to V-Go initiation dose, dose at first recorded HbA1c on V-Go (14-week mean), and dose at second recorded HbA1c on V-Go (27-week mean). *P\0.001 compared to baseline lower limit prescribed dose. HbA1c glycated hemoglobin, LSM least-squares mean, TDD total daily dose and can be discreetly administered [13] . A previous study noted patient satisfaction with V-Go stating it was simple to use, discreet, and comfortable to wear [11] . V-Go is indicated for any adult patient requiring insulin regardless of type of diabetes or use of concomitant anti-hyperglycemic medications. V-Go delivers a consistent and continuous basal insulin rate over a 24 h period, which may offer improved efficiency over subcutaneous basal injections. The on-demand bolus dosing feature may ease the transition to basal-bolus therapy when mealtime insulin is required in patients prescribed a basal only regimen or those naïve to insulin. Furthermore, in patients using MDI, the ability to deliver mealtime insulin as needed without an additional injection may facilitate patients getting the insulin they need to improve their glycemic control.
Fear of hypoglycemia has been reported as a reason patients delay starting insulin therapy [20] but in this study there was no difference in patient-reported hypoglycemia after switching to insulin therapy with V-Go. Fear of weight gain has been reported as another reason for delay in treatment intensification [20] . Patients in the study saw a mean increase in weight of only 1.5 kg from baseline to 27 weeks after switching to V-Go. Although the prescribed dose of insulin decreased, patients were likely administering their insulin more appropriately enabling a more efficient cellular uptake of glucose resulting in rehydration and weight gain. This change in weight was well-within what is expected with insulin therapy, and although the change was statistically significant, it was not clinically relevant.
Varying titration practices across clinicians in our centers could have impacted study Study outcomes were analyzed according to subsets of patients who had an increase, a decrease, or no change to concomitant anti-hyperglycemic medications. The analysis showed that patients with an increase in concomitant medications weighed significantly more and were prescribed a higher TDD of insulin prior to V-Go use than those patients with no change or a medication decrease. This is not surprising, as higher insulin doses are typically prescribed in patients with increased body weight, and it is reasonable to escalate treatment with an additional medication in patients already receiving a high TDD of insulin. After 
CONCLUSIONS
Our study supports the safety and effectiveness of V-Go in improving glycemic control in patients with sub-optimally controlled diabetes requiring insulin. V-Go is an appropriate therapy for a broad range of patients; statistically significant reductions in HbA1c were seen with V-Go use in all subsets of patients including type 2, type 1/LADA, naïve to insulin, and patients administering insulin prior to V-Go. Reports of hypoglycemia were similar prior to and after switching to V-Go.
Patients administering insulin at baseline experienced substantial decreases in HbA1c while requiring a lower TDD of insulin. V-Go offers an efficient and efficacious method of insulin delivery that can enhance patient compliance and optimize glycemic control.
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